Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis

Executive Summary

Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.

You may also be interested in...



FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands

Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.

Zeposia’s Ulcerative Colitis Approval Provides BMS’s Beachhead Into GI

The second US approval for the S1P receptor agonist brings Bristol into the gastrointestinal space, and is just the starting point for the pharma in that arena, the company told Scrip.

Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel